American Biogenetic deal

MABXA entered into a five-year collaboration with Heinz Nau at the Free University of Berlin to develop compounds to treat epilepsy and neurodegenerative disorders. MABXA will provide an undisclosed amount of funding in return for an exclusive worldwide license to resulting products. MABXA said Nau has developed a series of anti-epileptic agents without the common side-effects associated with existing anti-convulsants. ...